This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg, Germany

Christine Weinl-Tenbruck, Ph.D.
Senior Scientist, Dept. of Molecular Therapy at CureVac SE


2018-present Senior Scientist at CureVac SE in the Department of Molecular Therapy

2016 – 2017 Scientist at CureVac AG in the Department of Enabling Technologies

2006-2015 Postdoc at the Interfaculty Institute for Molecular and Cell Biology, University of Tuebingen, with focus on an endothelial-specific knockout mouse model of Serum Response Factor SRF

2003-2005 Postdoc at the Department of Anatomy, University of Cambridge, focusing on retinal axon guidance in the model organism Xenopus laevis

2000-2002 Dissertation at the Max-Planck-Institute for Developmental Biology, Tuebingen on retinal axon guidance

Agenda Sessions

  • mRNA-based Therapy Proves Superior to the Standard of Care for Treating Hereditary Tyrosinemia 1 in a Mouse Model